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 Abstract: 
We discuss calculations of probability distribution functions (PDF) representing 
uncertainties in projecting fatal cancer risk from galactic cosmic rays (GCR) and solar particle 
events (SPE). The PDF’s are used in significance tests of the effectiveness of potential radiation 
shielding approaches. Uncertainties in risk coefficients determined from epidemiology data, dose 
and dose-rate reduction factors, quality factors, and physics models of radiation environments are 
considered in models of cancer risk PDF’s. Competing mortality risks and functional correlations 
in radiation quality factor uncertainties are treated in the calculations. We show that the cancer 
risk uncertainty, defined as the ratio of the 95% confidence level (CL) to the point estimate is 
about 4-fold for lunar and Mars mission risk projections. For short-stay lunar missions (<180 d), 
SPE’s present the most significant risk, however one that is mitigated effectively by shielding, 
especially for carbon composites structures with high hydrogen content. In contrast, for long 
duration lunar (>180 d) or Mars missions, GCR risks may exceed radiation risk limits, with 95% 
CL’s exceeding 10% fatal risk for males and females on a Mars mission. For reducing GCR 
cancer risks, shielding materials are marginally effective because of the penetrating nature of 
GCR and secondary radiation produced in tissue by relativistic particles. At the present time, 
polyethylene or carbon composite shielding can not be shown to significantly reduce risk 
compared to aluminum shielding based on a significance test that accounts for radiobiology 
uncertainties in GCR risk projection.  
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1.  Introduction 
 
Exposures to astronauts from galactic cosmic rays (GCR), made-up of high-energy 
protons and heavy ions, and solar particle events (SPE), comprised largely of low to medium 
energy protons, are important safety concerns for space exploration. Radiation risks include 
carcinogenesis, degenerative tissue effects such as cataracts (Cucinotta et al., 2001a) or heart 
diseases (Preston et al., 2003, Howe et al., 2004, Yang et al., 1982), and acute radiation 
syndromes (NCRP, 2000). Other risks such as damage to the central nervous system (CNS) are a 
potential concern for the GCR heavy ions (NAS, 1996). In the past, career radiation limits have 
been based on fatal cancer risks.  For low Earth orbit (LEO) programs, an excess fatal risk of 3% 
is used as criteria for dose limits, which are applied using age and gender specific dose to risk 
conversion factors. Radiation risk projection models serve several roles, which include setting 
dose-to-risk conversion factors needed to set dose limits, projecting mission risks, and evaluating 
the effectiveness of shielding or other countermeasures. For mission planning and operations, 
NASA uses the model recommended in the NCRP Report No. 132 for estimating cancer risks 
from space (NCRP, 2000). This model is similar to approaches described by other radiation risk 
assessment committees or in the scientific literature, employing a life-table formalism, 
epidemiological assessments of excess risk in exposed cohorts, such as the atomic-bomb 
survivors, and estimates of dose and dose-rate reduction factors (DDREF) and linear energy 
transfer  (LET) dependent radiation quality factors. 
  
Recently, NASA has recognized that projecting uncertainties in cancer risk estimates 
along with point estimates should be a requirement for ensuring mission safety, because point 
estimates alone have limited value when the uncertainties in the factors that enter into cancer risk 
calculations are large. Estimates of 95% confidence intervals (CI) for various radiation protection 
scenarios are meaningful additions to the traditional point estimates, and can be used to explore 
the value of mitigation approaches, and of research that could narrow the various factors that 
enter into risk calculations. Uncertainties for low linear energy transfer (LET) radiation, such as 
gamma-rays, have been reviewed several times in recent years, and indicate that the major 
uncertainty is the extrapolation of cancer effects data from high to low doses and dose-rates 
(NCRP, 1997; BEIR, 1994). Other uncertainties include the transfer of risk across populations, 
and sources of error in epidemiology data including dosimetry, bias, and statistical limitations. 
For low LET radiation, probability distribution functions (PDF’s) were described previously 
(NCRP, 1997). In estimating cancer risks for space radiation, additional uncertainties occur 
related to estimating the biological effectiveness of protons and heavy ions, and predicting LET 
spectra at tissue sites (Cucinotta et al., 2001b). The limited understanding of heavy ion 
radiobiology has been estimated to be the largest contributor to the uncertainty for space radiation 
effects (NAS, 1996), and radiation quality factors found to contribute the major portion of the 
uncertainties in a previous study (Cucinotta et al., 2001b).  
 
In this paper we discuss modifications to our methodology for projecting cancer risk 
probability distributions for space missions, and apply the model to several space exploration 
mission scenarios including the evaluation of potential shielding approaches:  First, in our 
previous work we had assumed the normal approximation for summing the additive contributions 
of many radiation components at tissue sites behind spacecraft shielding. The fluence weighted 
variance for each GCR charge and energy group was summed using the square root of the sum of 
the squares to estimate the standard deviation and confidence intervals. In the present work, we 
have used direct sampling over organ weighted LET distributions for the estimation of the 95% 
CI’s, and show that a log-normal distribution results from the analysis. A second modification is 
related to the uncertainties in the radiation quality factors. Previously, we had considered the 
range of experimental data for appropriate endpoints in order to develop a subjective PDF for the 
quality factor. In the present paper, we treat the quality factor, Q(L), and its uncertainties as a 
functional relationship, which recognizes that values of Q(L) at different LET’s are in-fact 
correlated by underlying biophysical processes. The final improvement made here is to 
accumulate Monte-Carlo trials directly from the double-detriment life-table rather than the cancer 
mortality rate. The life-table approach is used because in our previous estimates of cancer risk for 
the Mars mission (Cucinotta et al., 2001b), the upper level of the 95% C.I. exceeded 10% 
mortality risk, and for we expect that competing causes of death may significantly compress the 
higher values in the distribution.  
 
Shielding is one approach that can be considered for mitigating radiation risks. 
Theoretical and computational efforts in the 1980’s and 1990’s have provided the basic 
understanding needed to design effective shielding approaches (Wilson et al., 1991, 1995, 
Cucinotta et al., 1998a). Materials of low atomic mass, especially hydrogen are expected to be 
optimal as radiation shields because they reduce the occurrence of secondary particles (neutrons, 
protons, and other recoils) and are more effective per unit mass of material in slowing down or 
stopping ions in atomic collisions, and fragmenting HZE ions. However, because relativistic ions 
in the GCR are not appreciably slowed down by appreciable amounts of any material, and are the 
largest inducer of secondary radiation produced in tissues, the role of shielding material selection 
for GCR is not clear. We show here that shielding materials can not be shown to have an 
important role in reducing GCR risks, because of their poor attenuation properties in any material 
combined with large risk model uncertainties. In contrast, exposures to SPE’s are effectively 
mitigated by most shielding materials and there is a substantial reduction in mass that occurs 
when lower mass materials are selected for spacecraft structures.  
 
2. Life-Table Methodology 
 
We use the double detriment life-table to estimate radiation cancer mortality risks. In this 
approach the age-specific mortality of a population is followed over their entire lifespan with 
competing risks from radiation and all other causes of death described (Bunger et al., 1981). For a 
homogeneous population receiving an effective dose E, at age aE, the probability of dying in the 
age-interval from a to a+1 is described by the background mortality-rate for all causes of death, 
M(a), and the radiation cancer mortality rate, m(E,aE,a), as 
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The survival probability to live to age, a, following an exposure, E, at age, aE, is  
 
∏−
=
−=
1
)],,(1[),,()2(
a
au
EE
E
uaEqaaES  
 
The excess lifetime risk (ELR) is the increased probability that an exposed individual will 
die from cancer and is defined by the difference in the conditional survival probabilities for the 
exposed and unexposed groups as 
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We use a finite cut-off of 101-years for the upper limit in Eq.(3) and expressions below. A 
minimum latency-time of 10-years is often used for low LET radiation (NCRP, 2000), however 
we will consider alternative assumptions for high-LET radiation. The risk of exposure induced 
death (REID) is the lifetime risk that an individual in the population will die from a cancer caused 
by his or her radiation exposure, defined by  
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In general, the value of the REID exceeds that of the ELR by about 10-20%. Vaeth and Pierce 
(1990) have discussed special cases where the ELR is ill-defined and suggested that the REID is 
the preferred quantity for radiation protection. Radiation risk calculations are based on population 
data, however are used to estimate risks for individuals. Population data reflect gender 
differences, however also change with calendar year and often used for projections far into the 
future. For the astronaut population, the appropriateness of using the US average population can 
be questioned, because the so-called “healthy worker” effect is expected for astronauts.  
  
For projecting lifetime cancer fatality risks, an age- and gender-dependent mortality rate 
per unit dose, estimated for acute gamma-ray exposures, is multiplied by the radiation quality 
factor and reduced by the dose- and dose-rate reduction factor (DDREF) (NCRP, 2000). 
Additivity of effects of each component in a radiation field is assumed. Radiation mortality rates 
are largely modeled using the Japanese atomic-bomb survivor data. For transferring risks from 
the Japanese to US population two models are often considered. A multiplicative transfer model 
assumes radiation risks are proportional to spontaneous or background cancer risks. The additive 
transfer model assumes radiation acts independently of other cancer risks. However, the NCRP 
recommends (NCRP, 2000) a mixture model with fractional contributions from the multiplicative 
risk model or additive risk model. The radiation mortality rate is: 
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 where ERR and EAR are the excess relative risk and excess additive risk per Sievert, respectively, 
Mc(a) is the gender and age-specific cancer mortality rate in the US population, F is the tissue-
weighted fluence and L is the LET. In Eq.(5), ν is the fractional division between the assumption 
of the multiplicative and additive risk transfer models. For solid-cancer, it is assumed that ν=1/2 
and for leukemia that ν=0.  
 
3. Uncertainties in the Projection Model  
 
Equation (5) consists of a product of several factors: the ERR or EAR,  the background 
cancer rates, Mc, the effective dose represented by the physical dose, FL, times the radiation 
quality factor, Q(L), and the dose- and dose-rate reduction factor, DDREF. The limiting behavior 
of the addition of many random variables is well known as the normal distribution. In contrast, 
the limiting behavior of the multiplication of many random factors will be a log-normal 
distribution. We next consider estimates of the range of values and associated PDF’s for each of 
these factors. Because the risk for longer duration missions exceeds a few percent, upper 95% CIs 
may exceed 10%. In such cases, the sampling of rates is insufficient and the expression for the 
REID given by Eq. (4) must be used because of competing risks from other causes of death that 
will reduce the likelihood of very large radiation risks. Therefore in the sampling approaches 
described below trials are accumulated for the REID rather than the mortality rate. A criteria used 
in our approach for formulating PDF’s for various factors is ensure the PDF’s are peaked at the 
values recommended by the NCRP (NCRP, 2000), such as the DDREF and Q,  or in the current 
physics models of radiation environments and transport used in mission projections or spacecraft 
designs. As described below the model of Eq. (5) assumes that the dependence of risk with time 
after exposure and latency effects is independent of radiation quality, despite experimental 
evidence to the contrary. We ignore these uncertainties; however we replace the 10-year minima 
latency assumption made for solid cancer risk from low LET irradiation, by the step-in latency 
model (Pierce et al., 1996) used for the leukemia risk. We next describe the PDF’s that represent 
the uncertainties in the projection model.  
 
For sampling purposes, the low-LET mortality-rate per Sievert, mL is written  
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where m0 is the baseline mortality rate per Sievert (see Eq. (5)) and the xα are quantiles (random 
variables) whose values are sampled from an associated probability distribution functions (PDF), 
P(xα). Note that the DDREF applies only to the solid cancer risk and not the leukemia risk under 
the stated assumptions. The NCRP Report 126 (NCRP, 1997) defines the following subjective 
PDF’s, P(xα), for  each factor that contributes to the low LET-risk projection: 
1. Pdosimetry represents the random and systematic errors in the estimation of the doses received 
by atomic-bomb blast survivors.   It is  assumed as a normally-distributed PDF for bias 
correction of random and systematic errors in the dosimetry (DS86) with mean 0.84 and 
standard deviation 0.11; 
2. Pstatistical represents the distribution in uncertainty in the risk coefficient r0. It is assumed as a 
normally distributed PDF with a mean of one and a standard deviation of 0.15;  
3. Pbias represents any bias resulting for over- or under-reporting cancer deaths. Pbias is assumed 
as a normal distribution with a most probable values of 1.1 and a 90% C.I. from 1.02 to 1.18 
corresponding to a standard deviation of 0.05; 
4.  Ptransfer represents the uncertainty in the transfer of cancer risk following radiation exposure 
from the Japanese population to the US population. Both additive and relative risks models 
were considered by NCRP 126 in assessing the uncertainties in such transfer. Ptransfer is log-
normal with mean 1 and standard deviation 0.26 (GSD=1.3); 
5. PDr represents the uncertainty in the knowledge of the extrapolation of risks to low dose and 
dose-rates, embodied in the dose and dose-rate reduction factor (DDREF). The NCRP 
assumed PDr to be a truncated triangle distribution starting at 1 and ending at 5 with a peak at 
2 with a relative value of ¼ or ½ at 1 or 5, respectively, compared to the peak values for the 
DDREF at 2. This PDF is used to scale the low LET risk coefficient (mortality rates) in our 
estimates for space radiation. 
 
The NCRP also considered a PDF for bias correction in projection of cancer risks over a 
lifetime. It is ignored herein because the astronaut population is generally over age 30 and the 
Japanese data is now complete for these ages. We also ignore the assumed “unknown 
uncertainties” from the NCRP 126 report (NCRP, 1997).  
 
Uncertainties Due to Radiation Quality Effects 
Radiation quality factors represent the largest uncertainty in estimating space radiation 
cancer risks. Past reviews on the relative biological effectiveness of high-LET radiation include 
the ICRU Report 40 (1986), NCRP Report 104 (1990), and more recently ICRP Report 92 
(2003). The practice of assigning radiation quality factors followed by committees is to consider 
an average of the relative biological effectiveness (RBE) factors at low doses (RBEmax) for the 
most relevant experimental endpoints.  Uncertainties in assignment of RBE’s for protons and 
heavy ions arise for several reasons including sparseness of data for tumorigenesis in animal 
models or surrogate tissue or cellular endpoints, variability in reference radiation and doses and 
dose-rates employed, and lack of data over the LET range of interest. Also, linearity at low dose 
or dose-rates for the reference radiation or ions is often not sufficiently established in 
experiments. Statistical limitations often hinder studies at the low dose-rates of interest for space 
radiation protection. For high-LET radiation, a turn-over or bending found in the dose response 
for tumor induction and neoplastic transformation is observed at moderate doses, presenting 
further uncertainties in estimating the effectiveness of high-LET radiation at low dose-rates.  
 
Figure 1 shows representative examples of the ratio of RBEmax to Q for mouse tumors, 
cell transformation or mutations, or cytogenetic endpoints. The ratio is often 2- to 3-fold times 
higher or lower than unity, which indicates the expected deviation from Q in available data. 
Table 1 shows LET values at the maximum RBE found in past studies, selected from 
experiments with more than 5 ions studied. Large deviations from the Q peak at 100 keV/µm are 
observed in these experiments with a range from about 50 to 190 keV/µm for the peak. The 
number of past studies and endpoints used are limited if viewed as surrogate endpoints for human 
carcinogenesis. Track structure models suggest that each ion species would have distinct RBE 
curves of similar shape, however with curves for lower charge ions peaking at a lower LET than 
higher charged ions (Katz et al., 1971; Cucinotta et al., 1996; Nikjoo et al., 1999). Furthermore, 
above about 1-MeV/u, lower charged ions have a higher biological effectiveness than higher 
charged ions of identical LET. Based on track structure models, we expect that data sets that 
consider only a few ions are insufficient for defining the radiation quality dependence of Q. LET 
response curves also are predicted to depend on the target size (for e.g. gene or chromosome 
region), and intrinsic radiation sensitivity, which includes the competition with cell death. These 
factors likely vary between tissues.  
 
To account for the uncertainties in quality factors, we introduce a trial function that has a 
shape guided both by experimental data and biophysical models, and sample from distributions of 
parameters that enter into the functional form. The Q(L) trial function is defined 
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We sample values of L0, Lm, p, and the maximum value, Qm(Lm) from PDF’s described below. 
Using Eq.(7) we can then solve for values of the constants A, B, and C. Often discussed issues on 
the definition of Q(L) as embodied in Eq.(7) are the value of slope p that controls the decrease in 
Q(L) above a maximum, the maximum value of Q(L), the LET where the maximum occurs, Lm, 
and the minimum LET where Q(L) rises above unity, L0 . We note the ICRP-60 Q-function 
corresponds to L0=10 keV/µm, Lm=100 keV/µm, p = ½, and Qm=30 such that A=0.32, B=2.2, C = 
300, and the ICRP-26 Q-function, L0=3.5 keV/µm, Lm=172.5 keV/µm,  p=0, and Qm=20.  
 
The parameter samplings are based on the following assumptions for PDF’s:  
a) L0:  equal probability between 5 and 10 keV/µm, and decreasing to zero at 1 keV/µm, or 
above 15 keV/µm. 
b) Lm:   equal probability for LET values between 75 and 150 keV/µm, and decreases to zero 
at 50 keV/µm or above 250 keV/µm. 
c) p:  equal probability between p=1/2 and 1, and decreasing to zero at p<0 or p>2.  
d) Qm: log-normal distribution with mean value of 30 and GSD of 1.8. 
 
Figure 2a shows examples of trial Q(L) functions that contribute in the sampling procedures, and 
Figure 2b shows the resulting average Q(L) and 95% CI after 20,000 trials. The resulting range is 
smaller than in our previous report (Cucinotta et al., 2001b), however should be a reasonable 
estimate when the effects of dose protraction are not included in the uncertainty analysis. 
 
Uncertainties in Physics: Environments and Transport Codes 
Space dosimetry and radiation transport codes have been studied extensively in the past, 
and although there are no major scientific questions that lead to errors in the assessment of space 
radiation environments, there are practical limitations in space dosimetry and accelerator bench 
mark tests, or because the level of detail used in application of transport codes when compared to 
flight or accelerator data is incomplete.  Common simplifications in flight comparisons to 
transport models are the use of an aluminum equivalent shielding approximation, simplified 
geometries, no description of orientation effects, and neglect of detector response functions 
(Nikjoo et al., 2002) for different radiation components.  Statistical errors in the assessment of 
physical doses are quite small (<5%), however inter-comparisons between laboratories have 
shown differences on the order of 10% for absorbed dose (Badhwar, 1997).  Commonly used 
detectors are tissue equivalent proportional counters (TEPC’s), silicon detectors, and CR-39 
plastic track detectors (Benton et al., 2002). Good agreement has been found in comparisons that 
have been made (see for e.g., Shinn et al., 1998; Badhwar and Cucinotta, 2000; Cucinotta et al., 
2000; Kim et al., 2003), especially when detector response functions are represented in the 
comparisons, however the number and nature of the comparisons is limited.  
The PDF’s for the uncertainties in LET spectra, should ensure the resulting dose 
equivalent is consistent with transport code comparisons to past spaceflight measurements for 
GCR. Based largely on comparisons of the HZETRN model to flight dosimetry results note 
above, a standard error of about 15% for projection of the GCR dose equivalent is expected. 
However, a higher uncertainty for specific values of F(L) are needed to account for the larger 
differences at higher LET flux values. We performed Monte-Carlo simulations which show that 
modest dose or dose equivalent differences between codes and data, do not prevent large 
deviations in flux versus LET comparisons to occur.  A quantile, xL, associated with a normal 
distribution, PF(xF=F/F0), where F0 is the baseline F(L) model, is used with a standard error that 
increases with LET to represent the higher uncertainties expected for prediction of neutron 
effects, and the difficulty in precisely defining stopping ions in complex geometries. The PDF is 
given a median of x0F=0.65 to ensure the resulting dose equivalent is in agreement with values 
from prior comparison between transport codes and flight measurements cited above. Standard 
deviations for different LET regions are given in Table 2. Results for the distribution of dose 
equivalents after sampling over LET spectra  for a 600 day mission in deep space are shown in 
Figure 3, and indicate the expected error in the dose equivalent based on comparisons of 
transport codes to flight measurements in the past.   
 
4.  PDF’s for Space Exploration Missions 
 
The cancer risk projection for space missions are found by folding predictions of the 
tissue-weighted LET spectra behind space craft shielding, dF/dL, with the radiation cancer 
mortality rate to form a rate for a trial J: 
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 (not shown are quantiles associated with low-LET mortality rate). Alternatively, particle specific 
energy spectra, Fj(E) for each ion, j, can be used: 
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 The result of equation (8) or (9) is then inserted into the expression for the REID of equation (4). 
In implementing a numerical procedure, we group the PDF’s related to the risk coefficient of the 
normal form, which consist of the dosimetry, bias, and statistical uncertainties into a combined 
PDF, Pcmb(x). After accumulating sufficient trials (~105), the results for the REID estimates are 
binned and the median values and confidence intervals found.  
  
 We use the χ2 test for determining if PDF’s for two distinct shielding configurations or 
materials are significantly different. We denote the calculated PDF’s for a REID of Ri for two 
configurations or materials as p1(Ri) and p2(Ri), respectively.  Each p(Ri) follows a Poisson 
distribution with variance, )( iRp . The chi-squared, χ2 test for characterizing the dispersion 
between the two distributions is then, 
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Once χ2 is determined, the probability P(n,χ2) that the two distributions are the same is 
calculated.  If χ2 is sufficiently large such that P(n,χ2) is less than about 20%, is an indication that 
we can conclude that the two distributions lead to distinct cancer risks from GCR and/or SPE’s, 
with the material with the lowest mean and upper 95% CL values preferred for radiation 
protection. However, the opposite result indicates that the either the materials are approximately 
the same, or that the uncertainties in risk models prevents us from concluding that either 
configuration or material is superior for radiation protection properties. We evaluate χ2  for the 
LET dependent parts of the uncertainties (quality factors and physics) separately, since only these 
contributions explicitly depend on the modification of radiation fields by shielding. 
 
5.  Results  
 
In the results described next we use values of ERR and EAR for solid cancers from the 
Japanese Longitudinal Lifespan Study Report No. 13 (Preston et al., 2003). Note that these values 
for females were found to about 15% lower than the prior Report No. 12 (Pierce et al., 1996) used 
by NCRP Report No. 132 (NCRP, 2000) and values for males nearly the same in Reports 12 and 
13. Values for ERR and EAR for leukemia were not updated in the latest report and we use the 
values from Pierce et al. (1996). We use life-tables (CDC, 2000) and background cancer 
mortality rates (SEER, 2000) for the average US population for the year 2000. For models we use 
the GCR free space environment of Badhwar et al. (1994b), the HZETRN transport code (Wilson 
et al., 1991, 1995), and the QMSFRG model of nuclear fragmentation cross-sections (Cucinotta 
et al., 2003). The CAMERA model (Billings and Yucker, 1973) is used for organ shielding with 
tissue weighting coefficients (NCRP, 2000). Figure 4 shows calculations of the point dose 
equivalent and the effective dose (tissue averaged organ dose equivalent) for various shielding 
materials calculated by the HZETRN/BRYNTRN codes for the solar minimum GCR 
environment and the August of 1972 SPE. Calculations predict that the effects of SPE are readily 
mitigated by shielding, the effects of GCR are not, and tissue shielding reduces the differences 
expected when comparing materials.  For hydrogen shielding, the GCR effective dose is larger 
than the point dose because target fragments in tissue contribute about 50% of the effective dose, 
even though very little secondary radiation is produced directly in the hydrogen shield. Clearly, 
calculations or measurements of point dose equivalents mis-represent the effectiveness of 
shielding because of the role of secondary radiation produced in tissue. For calculations, we use 
5, 10, and 20 g/cm2 as representative of minimal or average shields.  
 
Figure 5 shows calculations for the point estimate and 95% CI’s for risk versus LET for 
males exposed at age 40 y. The top panel shows risks at an absorbed dose of 0.01 Gy and the 
bottom panel at 0.1 Gy. The solid squares are the resulting “fold-uncertainty” defined as the ratio 
of the 95% CL to the point estimate. At high LET, a 5-fold uncertainty occurs at low absorbed 
dose, however at higher absorbed dose and near the peak LET effectiveness, the uncertainties are 
reduced to about 3-fold due to competing causes of death limiting the upper levels of risk from 
radiation.   
 
The variation of GCR and SPE over the solar cycle would be difficult to use as a trade 
variable in long-term planning and we therefore discuss calculations at solar minimum and near 
solar maximum. For solar maximum calculations, we assume the large solar particle event (SPE) 
of August, 1972 to occur during the inter-planetary part of the mission, and use a solar 
modulation parameter (Badhwar et al., 1994) of 1100 MV, typical of about two years past solar 
maximum, however when large SPE’s often occur. We use a 16 g/cm2 vertical height for the 
Mars CO2 atmosphere in our calculations. Table 3 shows fatal cancer risk projections at solar 
minimum for males and females of age 40 at the time of the mission. Cancer morbidity risks are 
about 50% higher than mortality risks described here. Calculations are made for minimally 
shielded spacecraft of 5 g/cm2 aluminum, and a heavily shielded one of 20 g/cm2. Similar 
calculations near solar maximum are shown in Table 4 with an SPE fluence equivalent to the 
August of 1972 SPE is assumed to have occurred. At solar minimum, it is seen that a four-fold 
addition of mass reduces the cancer risk by only about 15%. Results are different at solar 
maximum. Here a four-fold increase in shielding mass leads to more than two-fold reduction in 
cancer risk; solar protons are less penetrating than GCR and effectively mitigated by shielding. 
However for heavy shielding ( g/cm2), GCR dominates over SPE’s and further addition of 
shielding provides marginal reductions. Each SPE is unique and has distinct fluence and energy 
spectra, and dose rates, therefore the shielding thickness where GCR doses exceed SPE doses 
vary from event to event.  
20≥
 
An alternative to a shielding approach that adds mass is to optimize materials used in 
spacecraft structures or planetary habitats to reduce radiation risk. Figure 6 shows PDF’s for the 
GCR as solar minimum for aluminum, polyethylene, and liquid hydrogen shielding with areal 
density of 20 g/cm2. Table 5 shows results for the χ2 statistic comparing polyethylene and 
hydrogen shielding effectiveness to aluminum. For calculations that ignore the low LET risk 
coefficient uncertainties, near solar maximum with a large SPE, significant results (P<0.01) are 
found for liquid hydrogen, and for the GCR at solar minimum (with P<0.15). We conclude that 
because of the modest differences between polyethylene and aluminum as GCR absorbers, and 
the large radiobiological uncertainties in cancer risk projection models, the benefits of 
polyethylene compared to aluminum shielding for GCR can not be proven at this time. A key 
factor in these results is that although aluminum is a greater producer of secondary radiation 
compared to polyethylene, tissue shielding “equalizes” much of these differences.  
 
The formalism can be applied to estimate the number of days a mission is ensured to be 
below an exposure limit at a given confidence level. Because we use the REID quantity, and the 
newer LSS Report 13 (Preston et al., 2003) values for ELR and EAR compared to the NCRP 
Report 132 (NCRP, 2000), and consider limits for single missions rather than 10-year careers, we 
first calculated dose limits that result for the present model corresponding to 3% and 5% fatal 
cancer risk for missions of length < 3 yr. These are listed in Table 6, which also shows 
calculations of loss of life-expectancy (LLE) from radiation cancer induced cancers. In an earlier 
report (Cucinotta, et al. 2000b) we estimated the maximum number of days in deep space 
astronauts could spend with a 95% CL to remain below a 3% fatal cancer risk.  Table 7 updates 
these calculations and compares to the earlier report. The results show a significant increase in the 
number of “safe” days with 95% CL to remain below acceptable levels or risk that result from our 
improved methodology. However, the results are well short of that needed for a Mars mission. 
 
6. Discussion 
 
The building of PDF’s that propagate errors from individual factors that contribute to 
uncertainties in projection models is a powerful tool for managing radiation risks, including 
evaluating benefits of research and mitigation approaches and implementing the radiation 
protection principle of as low as reasonable achievable (ALARA). The uncertainties estimated 
here are reduced compared to our previous estimates (Cucinotta et al., 2001b, 2002, 2004) for the 
following reasons: 
1. Use of the REID rather than radiation cancer rates (decreases upper uncertainty level 
    because of role of competing risks) 
2. Use of trial Q(L) functions rather than uncorrelated uncertainties as a function of LET     
     (overall decrease in uncertainties) 
3. Neglect of NCRP “unknown” uncertainties (decrease in uncertainties) 
4. Re-defining LET-spectra uncertainties (modest increase in uncertainties). 
However, these estimates should be viewed as preliminary because of the need to assess 
additional uncertainties that have not been included in the analysis, including protraction effects, 
scaling of ERR’s or EAR’s estimated from low LET data to high LET’s, and the potential impact 
of a healthy worker effect. These factors will need to be considered in future work.  Low-LET 
epidemiology data and physics models uncertainties have a smaller role in the present evaluation. 
As noted in our earlier report (Cucinotta et al., 2001b), other uncertainties exist in the 
representation of radiation shielding composition and predicting future solar cycle effects or the 
characteristics of SPE’s; however these are more practical in nature and will be considered 
elsewhere. 
 
The methodologies used for risk assessment ultimately play a large role in the estimates 
of uncertainties and shielding effectiveness. The use of the linear-additivity model is a key 
assumption in the current methodology. This model has a strong basis in mouse carcinogenesis 
studies with low dose neutron irradiations (Storer and Fry, 1995), and for neutron exposures, a 
mixed low and high-LET field is present due to the gamma-rays produced by neutrons. Possible 
deviations from the linear-additivity model for the GCR spectrum along with correlations in 
estimates of DDREF, protraction effects and quality factors need to be considered in future work. 
Experiments that simulate the constant high-energy proton background with interspersed heavy 
nuclei irradiation such as iron would be a first-step in testing these effects. Further investigation 
of alternative methodologies that could possibly reduce uncertainty estimates should also be 
considered. However, the need for new biological data and understanding is the most important 
approach to reducing uncertainties.  
 
We have not made an estimate of the uncertainties based on radiation quality 
effects related to latency, time after exposure, or exposure protraction. The model of 
Eq.’s (1)-(5) assumes implicitly that these factors are independent of radiation quality. 
For low dose-rate and protracted proton and HZE radiation exposure of more than a few 
months, new biological factors may influence risk assessments including redistribution in 
the cell cycle, repopulation, or promotional effects, especially when particle fluences are 
large enough to lead to multiple hits of target cells or surrounding cells and tissue 
environments. Also, not only is there no human data for protons and HZE ions, there is 
very little experimental data at low dose-rates for these particles. Experimental data for 
protracted proton or heavy ion irradiation in experimental models of carcinogenesis is 
almost non-existent. Burns et al. (1994) found split doses of argon ions separated by a 
few hours up to one-day increased the risk of skin cancer in rats. Alpen et al. (1994) 
found using seven two-week fractions of 0.07 Gy of iron an increase in risk of 50% 
compared to a single acute dose of 0.4 Gy for Harderian gland tumors in mice.  A study 
of chromosomal aberrations in human lymphocytes (George et al., 2001) for acute and 
low dose-rates (0.08 Gy/hr) with 250 MeV protons, showed less sparring than found for 
gamma-rays.  The Skyhook study of Ainsworth et al. (1986) considered life-shortening in 
mice comparing single acute with weekly fractions of several ions, however the results 
were unclear with regards to any increase or decrease in risk. For gamma-rays and 
neutrons, a good number of studies for cancer induction or life-shortening in mice exists, 
showing sparring effects for gamma-rays, and that neutron effects may be increased due 
to protraction under certain conditions in some tissues (Ullrich, 1984; NCRP, 1990).  
Important questions related to the differences in life-span, cell turn-over rates, or 
mechanisms of initiation or promotion in humans and mice, make estimates of the effects 
of protraction on risk difficult. Data on tumors or genomic instability in mice with 
neutrons (Ullrich et al., 1984; 1998; NCRP, 1990) and the studies of rat or mammary 
carcinogenesis with HZE nuclei (Burns, et al., 1994;  Dicello et al., 2004), suggest that 
the latency time is appreciably reduced for high LET compared to low LET radiation. In 
the model described above, a radiation quality dependent latency is more important in the 
additive transfer model than the multiplicative transfer model, especially at younger ages 
of exposure.   
 
Career radiation limits and shielding requirements could also be impacted by new 
knowledge of fatal non-cancer risks from radiation exposure such as heart disease (Preston et al., 
2003; Howe et al., 2004; Yang et al., 1982) or damage to the central nervous system (CNS). 
Based on the Japanese survivor data (Preston et al., 2003), non-cancer risks are estimated to be 
small for the shorter lunar missions, but could lead to a significant risk for the Mars mission. The 
risk of heart disease for ions is largely unknown because only one report (considered a pilot study 
by the authors of the report)  has been made on the effects of HZE ions on heart disease (Yang et 
al., 1982), and human data for low LET radiation at low dose-rates is inconclusive on the level of 
risk to be expected (Howe et al., 2004; Cardis et al., 1995). CNS risks have the potential to 
impact both short-term and career radiation limits and mitigation approaches (NRC, 1996). 
 
We have shown that with regard to the GCR, the optimization of material selection and 
mass can not be put on a sound scientific basis because the reductions estimated from point 
estimates alone are only on the order of a 10-30% for most shielding materials, and when 
combined with the uncertainties in projection models non-significant results for risk reduction are 
found. It still may be reasonable to assume that risk is reduced when comparing hydro-carbon 
shields to aluminum or other metals, however application of ALARA is problematic since cost-
benefit analysis can not be properly performed under these conditions. In contrast, for acute risks, 
which are largely an absorbed dose and dose-rate effect, SPE’s are the major concern and the role 
of minimizing mass requirements through hyrdo-carbon shielding materials is easier to prove.  
 
The ALARA principle is an important aspect of radiation safety. Our estimate of 95% 
CL’s to stay below limits can be used as criteria for a minimal ALARA requirement for the 
design of lunar missions including transfer vehicle or surface habitat designs.  For example about 
a 4-fold margin can be used for GCR exposures and about a 2.5 fold margin for SPE’s. Detailed 
cost-benefit analysis should be used for measures that would provide even lower risks. Future 
work should consider a worst-case SPE environment including the possibility of multiple SPE’s 
as a function of mission duration.  Based on the results of Table 7 and the above margins, we 
conclude that “blind selection” of astronauts for lunar missions can be made for missions with 
duration less than 120 days for male or female astronauts above the age of 35-yrs, if sufficient 
protection against SPE’s is provided. Because of the higher GCR risks for the longer Mars 
missions or perhaps long-term lunar missions, and the likely impacts of non-cancer risks, no 
conclusions on ALARA goals for these missions or the possibility of “blind selection” can be 
made at this time. The inherent uncertainties in population based risk models and the higher risks; 
point to the likelihood that individual based risk assessments will be needed for Mars exploration 
missions.  
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Figure Captions 
 
Figure 1. Comparison of ratio of RBEmax to Q for several endpoints found with proton, 
alpha particle, and heavy ion irradiations (Reference to experiments listed in Table I).  
 
Figure 2a. Examples of trial quality factor functions used in uncertainty calculations. A 
distinct curve is generated for each trial.  
 
Figure 2b. Average quality factor (circles) and 95% CI’s versus LET that from Monte-
Carlo sampling over trial function of Eq. (7). 
 
Figure 3. PDF for GCR effective dose for 20 g/cm2 aluminum shield for 600-d Mars 
swing-by mission. The point estimate is 0.86 Sv, and the 95% CI for uncertainties in LET 
distribution at tissue sites is [0.78, 1.08] Sv. Only uncertainties in physics are included. 
 
Figure 4. Point dose equivalent (upper panel) and effective dose (bottom panel) behind 
various shields for solar minimum GCR and August 1972 SPE (the units for the SPE 
doses are for total event and not necessarily per year).  
 
Figure 5. Calculations of REID versus LET at doses of 0.01 or 0.1 Gy for 40-y males. 
Diamonds point estimates, bands 95% CI,  and squares the fold uncertainties.  
 
Figure 6. PDF’s for 40-y males for a 600-day Mars swing-by mission for 20 g/cm2 
shields of aluminum, polyethylene or liquid hydrogen.  Effective doses, and point 
estimates and 95% CI for REID are shown in box. 
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Table 1. Approximate LET where maximum RBE was found in biological experiments. 
Biological system Endpoint LET at peak 
RBE, keV/µm 
LET range (No. of 
ions studied) 
Reference 
Human TK6 
lymphoblasts cells 
TK mutants 60 32-190 (6) Kronenberg (1994) 
Human TK6 
lymphoblasts cells 
HPRT mutants 60 32-190  (6) Kronenberg (1994) 
Human lung 
fibroblasts 
HPRT mutants 90 20-470 (9) Cox and Masson 
(1979) 
Human Skin 
fibroblasts 
HPRT mutants 150 25-920 (7) Tsuoboi et al. 
(1992) 
V79 Chinese 
hamster cells 
HPRT mutants 90 10-2000 (16) Kiefer et al. (1994); 
Belli et al. (1993) 
Caenorhabditis 
elegans 
Recessive 
lethal 
mutations 
190 0.55-1110 (14) Nelson et al. (1989) 
Human 
lymphocyte cells 
Chromosomal 
exchanges 
147 0.4-1000 (10) George et al. 
(2003) 
Human fibroblast 
cells 
Chromatid 
breaks 
80-185 13-440 (6) Kawata et al. 
(2001) 
C3H10T1/2 mouse 
cells 
Transformation 140 10-2000 (10) Yang et al. (1989) 
C3H10T1/2 mouse 
cells 
Transformation 90 20-200 (10) Miller et al. (1995) 
Syrian hamster 
embryo (SHE) 
cells 
Transformation 90 20-200 (8) Martin et al. (1995) 
Mouse (B6CF1) H. gland 
tumors 
185* 2-650 (6) Fry et al. (1985) 
Mouse (B6CF1) H. gland 
Tumors 
193 0.4-1000 (7) Alpen et al. (1993) 
Mouse (CB6F1)  Days life lost 52* 50-500 (6) Ainsworth (1986) 
*Track-segment or spread-out Bragg peak (SOBP) irradiations. 
 
 
 
 
 
Table 2. Standard deviations for uncertainties in model LET spectra for several LET regions. 
 
LET Interval S.D. for dF/dL 
< 30 keV/µm  1.0 
30-300 keV/µm  2.0 
> 300 keV/µm  2.5 
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Table 3a. Calculations of effective doses, REID, and 95% CI for lunar or 
Mars missions. Calculations are at solar minimum for a 5-g/cm2 aluminum 
shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
    Males (40 y) 
Lunar-long 0.03 0.084 0.34 [0.10, 1.2] 
Mars 
swingby 
0.37 1.03 4.0 [1.0, 13.5] 
Mars 
surface 
0.42 1.07 4.2  [1.3, 13.6] 
    Females (40 y) 
Lunar-long 0.03 0.084 0.41 [0.12, 1.5] 
Mars 
swingby 
0.37 1.03 4.9 [1.4, 16.2] 
Mars 
surface 
0.42 1.07 5.1  [1.6, 16.4] 
 
 
Table 3b. Calculations of effective doses, REID, and 95% CI for lunar 
or Mars missions. Calculations are at solar minimum for a 20-g/cm2 
aluminum shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
    Males (40 y) 
Lunar-long 0.03 0.071 0.28 [0.09, 0.95] 
Mars 
swingby 
0.36 0.87 3.2 [1.0, 10.4] 
Mars 
surface 
0.41 0.96 3.4  [1.1, 10.8] 
    Females (40 y) 
Lunar-long 0.03 0.071 0.34 [0.11, 1.2] 
Mars 
swingby 
0.36 0.87 3.9 [1.2, 12.7] 
Mars 
surface 
0.41 0.96 4.1  [1.3, 13.3] 
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Table 4a. Calculations of effective doses, REID, and 95% CI for lunar or 
Mars missions. Calculations are near solar maximum assuming 1972 SPE 
in deep space segment of mission with a 5-g/cm2 aluminum shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
  Males (40 y) 
Lunar-long 0.45 0.69 2.7 [0.95, 7.6] 
Mars 
swingby 
0.62 1.21 4.4 [1.5, 13.1] 
Mars 
surface 
0.66 1.24 4.8 [1.6, 14.2] 
  Females (40 y) 
Lunar-long 0.45 0.69 3.3 [1.1, 9.3] 
Mars 
swingby 
0.62 1.21 5.7 [1.8, 17.1] 
Mars 
surface 
0.66 1.24 5.8 [2.0, 17.3 ] 
 
 
Table 4b. Calculations of effective doses, REID, and 95% CI for lunar or 
Mars missions. Calculations are near solar maximum assuming 1972 SPE 
in deep space segment of mission with a 20-g/cm2 aluminum shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
  Males (40 y) 
Lunar-long 0.04 0.09 0.36 [0.12, 1.2] 
Mars 
swingby 
0.22 0.54 2.0 [0.60, 6.8] 
Mars 
surface 
0.25 0.60 2.4 [0.76, 7.8] 
  Females (40 y) 
Lunar-long 0.04 0.09 0.43 [0.13, 1.4] 
Mars 
swingby 
0.22 0.54 2.5 [0.76, 8.3] 
Mars 
surface 
0.25 0.60 2.9 [0.89, 9.5] 
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Table 5a. χ2 test at solar minimum for 20 g/cm2 shields for 40-yr males on Mars swing-by 
mission.  P(n, χ2) is the probability materials can not be determined to be significantly different 
(n=500).  Values in bold for P(n, χ2)<0.2 indicate a significant improvement over aluminum. 
 
Test Material E, Sv REID(%) 95% CL χ2/n P(n,χ2)   
 All Uncertainties 
Aluminum 0.87 3.2 [1.0, 10.5] - - 
Polyethylene 0.78 2.9 [0.94, 9.2] 0.05 >0.99 
Hydrogen 0.43 1.6 [0.52, 5.1] 0.63 >0.99 
 LET-dependent Uncertainties 
Aluminum 0.87 3.2 [1.9, 8.7] - - 
Polyethylene 0.78 2.9 [1.8, 7.5] 0.08  >0.99 
Hydrogen 0.43 1.7 [1.0, 4.2] 1.10 <0.15 
 
Table 5b. Same as Table 5a near solar maximum for 5 g/cm2  shields. 
 
Test Material E, Sv REID(%) 95% CL χ2/n P(n,χ2)   
 All Uncertainties 
Aluminum 1.21 4.4 [1.5, 13.1] - - 
Polyethylene 0.94 3.5 [1.2, 10.8] 0.14 >0.99 
Hydrogen 0.52 2.1 [0.60, 6.4] 0.81 >0.99 
 LET-dependent Uncertainties 
Aluminum 1.21 4.4 [3.0. 11.0] - - 
Polyethylene 0.94 3.5 [2.3, 8.8] 0.32 >0.99 
Hydrogen 0.52 2.1 [1.2, 5.2] 1.38 <0.001 
 
Table 5c.  Same as Table 5a near solar maximum for 20 g/cm2 shields. 
 
Test Material E, Sv REID(%) 95% CL χ2/n P(n,χ2)   
 All Uncertainties 
Aluminum 0.54 2.0 [0.60, 6.8] - - 
Polyethylene 0.45 1.7 [0.52, 5.6] 0.08 >0.99 
Hydrogen 0.24 0.9 [0.27, 2.9] 0.77 >0.99 
 LET-dependent Uncertainties 
Aluminum 0.54 2.0 [1.2, 5.6] - - 
Polyethylene 0.45 1.7 [1.0, 4.6] 0.15 >0.99 
Hydrogen 0.24 0.9 [0.52, 2.4] 1.26 <0.005 
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Table 6a. Example career effective dose limits in units of Sievert (Sv) for 1-year missions and 
corresponding average life-loss for an exposure induced death. 
 
 E, Sv for 3% REID (Ave. Life Loss per Death, yr) 
Age, yr Males Females 
25 0.5  (15.7) 0.4 (15.9) 
30 0.6  (15.4) 0.5 (15.7) 
35 0.7  (15.0)  0.55 (15.3) 
40 0.8  (14.2) 0.6 (14.7) 
45 0.95  (13.5)  0.75 (14.0) 
50 1.15  (12.5) 0.9 (13.2) 
55 1.5  (11.5) 1.1 (12.2) 
 
Table 6b. Example career effective dose limits in units of Sievert (Sv) for 1-year missions and 
corresponding average life-loss for an exposure induced death. 
 
 E, Sv for 5% REID (Ave. Life Loss per Death, yr) 
Age, yr Males Females 
25 0.9  (15.7) 0.6 (15.9) 
30 1.0  (15.4) 0.8 (15.7) 
35 1.2  (15.0) 0.9 (15.3) 
40 1.3  (14.2) 1.0 (14.7) 
45 1.6  (13.5)  1.25 (14.0) 
50 1.9  (12.5) 1.5 (13.2) 
55   2.45 (11.5) 1.9 (12.2) 
 
 
Table 7a. Projections for males of age-dependent maximum days in deep space with 95% CL of 
remaining below a risk limit, RL(%). Calculations are for GCR at solar minimum with 10 g/cm2 
aluminum shielding comparing previous results (Cucinotta et al., 2001b) to present results. 
 
Age, yr Previous RL=3% Present RL= 3% Present RL= 5% 
30 91 142 236 
35 104 166 277 
40 122 186 310 
45 148 224 373 
50 191 273 455 
55 268 340 568 
 
Table 7b. Projections for females of age-dependent maximum days in deep space with 95% CL 
of remaining below a risk limit, RL(%). Calculations are for GCR at solar minimum with 10 g/cm2 
aluminum shielding comparing previous results (Cucinotta et al., 2001b) to present results. 
 
Age, yr Previous RL=3% Present RL= 3% Present RL= 5% 
30 54 112 187 
35 62 132 220 
40 73 150 250 
45 89 182 304 
50 115 224 374 
55 159 282 470 
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